Upregulation of TNF receptor type 2 in human and experimental renal allograft rejection

American Journal of Transplantation

Volumn 9, Issue 4, 2009, Pages 675-686

  Hoffmann, U ^a   Bergler, T ^a   Rihm, M ^a   Pace, C ^a   Kruger B ^b   Rummele P ^a   Stoelcker, B ^a   Banas, B ^a   Mannel D N ^a   Kramer B K ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Allograft rejection; Human and experimental kidney transplantation; Immunohistochemistry; mRNA analysis; Renal function; TNFR2

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; TUMOR NECROSIS FACTOR RECEPTOR 2;

ACUTE GRAFT REJECTION; ACUTE KIDNEY TUBULE NECROSIS; ACUTE VASCULAR REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TUBULE EPITHELIUM; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; UNINEPHRECTOMY; URINALYSIS;

EID: 63349097485     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02536.x     Document Type: Article

References (56)

1. Hribova P, Kotsch K, Brabcova I, Vitko S, Volk HD, Lacha J. Cytokines and chemokine gene expression in human kidney transplantation. Transplant Proc 2005 37 : 760 763.
2. Oliveira SG, Oliveira IB, Abensur H, Araujo MR, Romao JE, Noronha IL. Differential expression of cytokines, growth factors, and alpha-smooth muscle actin in renal allograft biopsies. Transplant Proc 2002 34 : 479 481.
3. Melk A, Henne T, Kollmar T et al. Cytokine single nucleotide polymorphisms and intrarenal gene expression in chronic allograft nephropathy in children. Kidney Int 2003 64 : 314 320.
4. Kondo S, Sauder DN. Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF-alpha-induced skin inflammation. Eur J Immunol 1997 27 : 1713 1718.
5. Tracey KJ, Cerami A. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target. Annu Rev Med 1994 45 : 491 503.
6. Luster AD. Chemokines - Chemotactic cytokines that mediate inflammation. N Engl J Med 1998 338 : 436 445.
7. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990 70 : 427 451.
8. Nagano H, Tilney NL, Stinn JL et al. Deficiencies of IL-4 or TNF-alpha receptor-1 do not diminish graft arteriosclerosis in cardiac allografts. Transplant Proc 1999 31 : 152.
9. Brown GR, Lee E, Thiele DL. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J->C57BL/6J × bm12)F1 mice. J Immunol 2002 168 : 3065 3071.
10. Al-Lamki RS, Wang J, Skepper JN, Thiru S, Pober JS, Bradley JR. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 2001 81 : 1503 1515.
11. Ramesh G, Reeves WB. Inflammatory cytokines in acute renal failure. Kidney Int Suppl 2004 S56 S61.
12. Zager RA, Johnson AC, Hanson SY, Lund S. Ischemic proximal tubular injury primes mice to endotoxin-induced TNF-alpha generation and systemic release. Am J Physiol Renal Physiol 2005 289 : F289 F297.
13. Ramesh G, Reeves WB. Inflammatory cytokines in acute renal failure. Kidney Int Suppl 2004 S56 S61.
14. Donnahoo KK, Meng X, Ao L et al. Differential cellular immunolocalization of renal tumour necrosis factor-alpha production during ischaemia versus endotoxaemia. Immunology 2001 102 : 53 58.
15. Liu M, Chien CC, Burne-Taney M et al. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J Am Soc Nephrol 2006 17 : 765 774.
16. Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 2007 72 : 37 44.
17. Suenaert P, Bulteel V, Lemmens L et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002 97 : 2000 2004.
18. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003 4 : 429 437.
19. Lans TE, Bartlett DL, Libutti SK et al. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. Clin Cancer Res 2001 7 : 784 790.
20. O'Dell JR. Anticytokine therapy - A new era in the treatment of rheumatoid arthritis? N Engl J Med 1999 340 : 310 312.
21. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997 337 : 141 147.
22. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000 356 : 385 390.
23. Torre-Amione G, Wallace CK, Young JB et al. The effect of etanercept on cardiac transplant recipients: A study of TNFalpha antagonism and cardiac allograft hypertrophy. Transplantation 2007 84 : 480 483.
24. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713 723.
25. Hoffmann U, Segerer S, Rummele P et al. Expression of the chemokine receptor CXCR3 in human renal allografts - A prospective study. Nephrol Dial Transplant 2006 21 : 1373 1381.
26. Vielhauer V, Stavrakis G, Mayadas TN. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest 2005 115 : 1199 1209.
27. Al-Lamki RS, Wang J, Skepper JN, Thiru S, Pober JS, Bradley JR. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 2001 81 : 1503 1515.
28. Al-Lamki RS, Wang J, Vandenabeele P et al. TNRR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J 2005 19 : 1637 1645.
29. Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten BI, Weening JJ. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 2000 11 : 1426 1438.
30. Hamano Y, Grunkemeyer JA, Sudhakar A et al. Determinants of vascular permeability in the kidney glomerulus. J Biol Chem 2002 277 : 31154 31162.
31. Fernandez-Fresnedo G, Plaza JJ, Sanchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M. Proteinuria: A new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 2004 19 (Suppl 3 iii47 iii51.
32. Alonso A, Oliver J. Causes of death and mortality risk factors. Nephrol Dial Transplant 2004 19 (Suppl 3 iii8 iii10.
33. Fernandez-Fresnedo G, Plaza JJ, Sanchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M. Proteinuria: A new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 2004 19 (Suppl 3 iii47 iii51.
34. Roodnat JI, Mulder PG, Rischen-Vos J et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001 72 : 438 444.
35. Vielhauer V, Stavrakis G, Mayadas TN. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest 2005 115 : 1199 1209.
36. Al-Lamki RS, Wang J, Skepper JN, Thiru S, Pober JS, Bradley JR. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 2001 81 : 1503 1515.
37. Al-Lamki RS, Wang J, Vandenabeele P et al. TNRR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J 2005 19 : 1637 1645.
38. Burton CJ, Combe C, Walls J, Harris KP. Secretion of chemokines and cytokines by human tubular epithelial cells in response to proteins. Nephrol Dial Transplant 1999 14 : 2628 2633.
39. Jevnikar AM, Brennan DC, Singer GG et al. Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha. Kidney Int 1991 40 : 203 211.
40. Hehlgans T, Seitz C, Lewis C, Mannel DN. Hypoxic upregulation of TNF receptor type 2 expression involves NF-IL-6 and is independent of HIF-1 or HIF-2. J Interferon Cytokine Res 2001 21 : 757 762.
41. Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2003 285 : F610 F618.
42. Mengel M, Gwinner W, Schwarz A et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007 7 : 356 365.
43. Tsai EW, Rianthavorn P, Gjertson DW, Wallace WD, Reed EF, Ettenger RB. CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. Transplantation 2006 82 : 1769 1773.
44. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003 349 : 2326 2333.
45. Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA, Griffin MD. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int 2007 71 : 619 628.
46. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995 54 : 1 8.
47. Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders. Int Rev Immunol 1998 17 : 217 228.
48. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992 89 : 4845 4849.
49. Dhillon S, Lyseng-Williamson KA, Scott LJ. Etanercept: A review of its use in the management of rheumatoid arthritis. Drugs 2007 67 : 1211 1241.
50. Sieper J, Van Den BJ. Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum 2005 34 (Suppl 1 23 27.
51. Levine JE, Paczesny S, Mineishi S et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008 111 : 2470 2475.
52. Sieper J, Van Den BJ. Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum 2005 34 (Suppl 1 23 27.
53. Torre-Amione G, Wallace CK, Young JB et al. The effect of etanercept on cardiac transplant recipients: A study of TNFalpha antagonism and cardiac allograft hypertrophy. Transplantation 2007 84 : 480 483.
54. Beyaert R, Vanhaesebroeck B, Declercq W et al. Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis. J Biol Chem 1995 270 : 23293 23299.
55. Funk JO, Walczak H, Voigtlander C et al. Cutting edge: Resistance to apoptosis and continuous proliferation of dendritic cells deficient for TNF receptor-1. J Immunol 2000 165 : 4792 4796.
56. Goukassian DA, Qin G, Dolan C et al. Tumor necrosis factor-alpha receptor p75 is required in ischemia-induced neovascularization. Circulation 2007 115 : 752 762.